Hepatobiliary Cancers | Meet The Professor: Optimizing the Management of Hepatobiliary Cancers — Part 2

Featuring perspectives from Dr Robin "Katie" Kelley, including the following topics:

• Introduction (0:00)
• Case: A man in his mid 80s with newly diagnosed hepatocellular carcinoma (HCC) who has a partial response with atezolizumab/bevacizumab — Minesh Dinubhai Patel, MD (15:01)
• Case: A man in his mid 60s with HCC and lung metastases (AFP = 30,000) who receives front-line atezolizumab/bevacizumab — Warren S Brenner, MD (30:17)
• Case: A man in his mid 60s with metastatic HCC and rapid disease progression on first-line atezolizumab/bevacizumab — Shaachi Gupta, MD, MPH (34:56)
• Case: A man in his early 80s with NASH liver cirrhosis and advanced HCC who develops proteinuria on atezolizumab/bevacizumab — Liudmila N Schafer, MD (39:09)
• Journal Club with Dr Kelley (42:53)
• Case: A woman in her early 70s with metastatic pancreaticobiliary cancer thought to be intrahepatic cholangiocarcinoma — Priya Rudolph, MD, PhD (48:39)
• Case: A woman in her late 40s with intrahepatic cholangiocarcinoma and micrometastases in portal lymph nodes — Pavel A Levin, MD, PhD (59:13)

CME information and select publications